Drug Decriminalization Success: Former White House Drug Czar Urges U.S. to Embrace Portugal’s Trailblazing Approach
A groundbreaking approach to drug policy has caught the attention of a former acting White House drug czar, leading to a powerful call for the United States to learn from Portugal’s remarkable success in decriminalizing drugs and addressing addiction as a health issue through a harm reduction approach.
Regina LaBelle, who held key positions in the Office of National Drug Control Policy (ONDCP) during both the Obama and Biden administrations, recently penned an op-ed published in The Hill. In this piece, she passionately advocates for the adoption of Portugal’s comprehensive public health-based drug policy, which includes decriminalizing personal drug possession while maintaining criminal penalties for drug trafficking. This approach was implemented at a time when Portugal faced a severe heroin addiction crisis and the highest rate of HIV infections in the European Union.
LaBelle highlights the significant positive results of Portugal’s drug policy, with drug overdose death rates now among the lowest in the European Union. The former drug czar acknowledges that while the current ONDCP under the Biden administration has promoted harm reduction policies and a review of marijuana’s scheduling status, broader drug decriminalization has not been supported. Thus, her call for reform is particularly noteworthy and deserving of attention.
Drawing on her expertise as the director of the Addiction and Public Policy Initiative at Georgetown University Law Center’s O’Neill Institute, LaBelle addresses a recent critique of Portugal’s decriminalization model published in The Washington Post. She asserts that consistent funding is a crucial element for sustaining long-term positive outcomes, which is one of the key lessons the U.S. can learn from Portugal.
The first vital lesson LaBelle advocates for is treating addiction as a public health issue rather than a criminal legal matter. Although the U.S. has made some progress in recognizing substance use disorder as a disease and reforming drug policies, there has been a resurgence of focus on criminalization in response to the emergence of substances like fentanyl. This shift in perspective is essential to effectively combat the drug crisis.
Investing substantial and consistent funding in public health services, including treatment and harm reduction, forms the second crucial lesson from Portugal’s approach. LaBelle points out that with opioid litigation proceeds and federal grants, the U.S. currently has a unique opportunity to invest in long-term public health solutions. She emphasizes that such investments not only save lives but also prove cost-effective in reducing crime.
The third imperative lesson that the U.S. can glean from Portugal is making robust financial investments in data collection and reporting. Understanding what strategies are effective and what needs improvement is paramount as the country combats the overdose crisis. Armed with comprehensive data, the U.S. can make more informed decisions in addressing the drug epidemic.
In the context of recent appointments and statements from influential figures like ONDCP Director Rahul Gupta and National Institute on Drug Abuse (NIDA) Director Nora Volkow, LaBelle’s call for a compassionate and health-centered approach to drug policy aligns with a growing sentiment in various medical associations. The American Pharmacists Association (APhA) and the American Society of Addiction Medicine (ASAM) have both endorsed drug decriminalization for public health and racial equity reasons, while the Minnesota Medical Association (MMA) supports broad drug decriminalization, expungements, and harm reduction programs.
In conclusion, the United States has a unique opportunity to learn from Portugal’s successful drug decriminalization model. By adopting a health-centered approach, consistently funding public health initiatives, and investing in data-driven strategies, the U.S. can enhance its response to the drug crisis, prioritize access to treatment, and ultimately save lives. The former drug czar’s advocacy adds to the growing chorus of voices pushing for reform and compassion in drug policy, providing hope for a more effective and inclusive approach to tackling addiction and its consequences.
